Lin Ping, Lin Maozeng, Lu Weiwei, et al. Clonazepam in the Treatment of a Case of Hyperekplexia Induced by GLRA Gene Mutation. [J]. 28(7):46-49(2022)
DOI:
Lin Ping, Lin Maozeng, Lu Weiwei, et al. Clonazepam in the Treatment of a Case of Hyperekplexia Induced by GLRA Gene Mutation. [J]. 28(7):46-49(2022) DOI: 10.13407/j.cnki.jpp.1672-108X.2022.07.012.
Clonazepam in the Treatment of a Case of Hyperekplexia Induced by GLRA Gene Mutation
treatment and genetic characteristics of a case of neonatal hyperekplexia and improve the understanding of the disease. Methods: The clinical diagnosis
treatment and follow-up process of a child with hyperekplexia admitted into our hospital in Jul. 2019 were summarized. From CNKI
PubMed and Wanfang database
the retrieval time was from the establishment of the database to Feb. 2020
and the cases of hyperekplexia with GLRA gene mutation at home and abroad were summarized and analyzed. Results: A newborn boy was admitted for “postnatal increased muscle tone
sharp and monotonous cry
accompanied by startle”
and the symptoms persisted nearly every day. Physical examination revealed positive dot nose test and increased muscle tone. Laboratory examination
electroencephalography and neuroimaging examination showed no obvious abnormalities
and the diagnosis of hyperekplexia was made. Genetic analysis revealed GLRA1 gene mutation
and the child was a new mutation. The child was treated with oral clonazepam
and the above symptoms were relieved after 2 weeks of treatment. At the last follow-up
the child was over 7 months of age and cried like the normal child of the same age
and did not show any signs of startle or general stiffness. Conclusion: Positive dot nose test is important for initial screening of hyperekplexia
and genetic testing can be used for further confirmation.